Pdl Biopharma, Inc. PDLI
We take great care to ensure that the data presented and summarized in this overview for PDL BIOPHARMA, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PDLI
Top Purchases
Top Sells
About PDLI
Insider Transactions at PDLI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2021
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
187,061
+0.77%
|
$374,122
$2.05 P/Share
|
|
Dec 30
2020
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
6,325,213
+21.01%
|
$12,650,426
$2.5 P/Share
|
|
Dec 30
2020
|
David W Gryska Director |
SELL
Open market or private sale
|
Direct |
20,000
-93.51%
|
$40,000
$2.74 P/Share
|
|
Dec 29
2020
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
268,600
+1.52%
|
$537,200
$2.69 P/Share
|
|
Dec 28
2020
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
235,000
+1.35%
|
$470,000
$2.7 P/Share
|
|
Dec 24
2020
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
128,000
+0.75%
|
$256,000
$2.65 P/Share
|
|
Dec 23
2020
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
485,000
+2.8%
|
$970,000
$2.6 P/Share
|
|
Dec 22
2020
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
850,000
+4.94%
|
$1,700,000
$2.59 P/Share
|
|
Dec 22
2020
|
John Peter Mclaughlin Director |
SELL
Open market or private sale
|
Direct |
277,934
-58.15%
|
$555,868
$2.61 P/Share
|
|
Dec 21
2020
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
230,000
+1.46%
|
$460,000
$2.63 P/Share
|
|
Dec 21
2020
|
John Peter Mclaughlin Director |
SELL
Open market or private sale
|
Direct |
50,000
-9.47%
|
$100,000
$2.62 P/Share
|
|
Dec 17
2020
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
398,000
+2.54%
|
$796,000
$2.61 P/Share
|
|
Dec 16
2020
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,350,000
+8.33%
|
$2,700,000
$2.58 P/Share
|
|
Dec 16
2020
|
David W Gryska Director |
SELL
Open market or private sale
|
Direct |
75,000
-77.81%
|
$150,000
$2.68 P/Share
|
|
Dec 16
2020
|
Dominique Monnet President and CEO |
SELL
Open market or private sale
|
Direct |
500,000
-40.49%
|
$1,000,000
$2.6 P/Share
|
|
Dec 16
2020
|
Christopher Lewis Stone VP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
200,000
-33.03%
|
$400,000
$2.56 P/Share
|
|
Dec 15
2020
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,000,000
+6.89%
|
$2,000,000
$2.59 P/Share
|
|
Dec 14
2020
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
640,000
+4.87%
|
$1,280,000
$2.62 P/Share
|
|
Dec 11
2020
|
Silver Point Capital L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
450,000
+3.65%
|
$900,000
$2.45 P/Share
|
|
Dec 05
2020
|
David W Gryska Director |
BUY
Exercise of conversion of derivative security
|
Direct |
66,050
+40.66%
|
$66,050
$1.64 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders